OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

management during today's call. The company will also be discussing certain non-GAAP financial measures which it believes are useful in evaluating the company's operating results. A reconciliation of such non-GAAP financial measures is included in the earning release the company issued this afternoon as well as in the investor relations section of the company's website. I would like to remind everyone that today's call has been recorded and will be made available for replay as an audio recording of this conference call on the investor relations section of the company's website. I would now like to turn the conference over to OptimizeRx CEO, Steve Silvestro. Mr. Silvestro, please go ahead. Thank you, Operator, and good afternoon to everyone joining today's first quarter 2025 call. I'm delighted to share our first quarter 2025 results, which came in ahead of both consensus estimates and our internal expectations. Momentum from Q4 has continued into 2025 with Q1 revenues increasing 11% year-over-year to $21.9 million, with adjusted EBITDA coming in at $1.5 million, an improvement of nearly $2 million year-over-year during what is typically our seasonally weakest quarter. Moreover, our contracted revenue continues to increase to more than 20% year over year, which positions us favorably going to the back half of the year. I believe this is a clear indicator that our focus on operational excellence while ensuring we delight our customers and forge stronger relationships with valued business partners is bearing fruit. In addition, despite media coverage in the market related to initiatives being implemented by the new administration, we are not seeing significant headwinds directly impacting our business at this time. and we are closely monitoring pharma leading indicators...